Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
W. P. T. James(University of Memphis), Cheryl Renz(Thermo Fisher Scientific (United States)), Nick Finer(University College London), Walmir Coutinho(Pontifícia Universidade Católica do Rio de Janeiro), Christian Torp‐Pedersen(University of Copenhagen), Aldo P. Maggioni(Health Care Foundation), Richard A. Rode(Abbott Fund), Luc F. Van Gaal(University of Antwerp), Arya M. Sharma(Rutgers, The State University of New Jersey), Gillian Shepherd(Abbott Fund), Ian D. Caterson(The University of Sydney)
Cited by 932
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
|The Lancet|2005|2.9k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k